About

About Unicycive UNICYCIVE was founded in August 2016 by Shalabh Gupta, MD, with the goal of building a company to solve the most pressing unmet medical needs in renal diseases. In 2018, Dr. Gupta licensed our first two technologies—UNI-494 and Oxylanthanum Carbonate (OLC)—with the help of a small but mighty team of industry-leading researchers and developers. Over the last five years our team has worked tirelessly to refine the technologies and help realize their full potential in patients with kidney diseases. In the process, we created a unique biotech system to prospect, unearth, refine, and create value with other technologies and in other disease states that also have pressing unmet medical needs. As we advance our existing technologies, we continue to look opportunistically for additional assets by identifying potential that others miss and partnering with promising therapeutic candidates that match our vision and mission. Our goal as an organization remains intently focused on bringing to market game-changing solutions quickly and efficiently for indications where patients continue to go underserved. At Unicycive, we know that only together can we advance science and medicine to make the biggest impact for patients, physicians, investors, and the healthcare community at large.